415 related articles for article (PubMed ID: 26980021)
1. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
[TBL] [Abstract][Full Text] [Related]
2. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
McGinnis LM; Nybakken G; Ma L; Arber DA
Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
[TBL] [Abstract][Full Text] [Related]
4. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
6.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
7. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
11. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.
Kamionek M; Ahmadi Moghaddam P; Sakhdari A; Kovach AE; Welch M; Meng X; Dresser K; Tomaszewicz K; Cosar EF; Mark EJ; Fraire AE; Hutchinson L
Histopathology; 2016 Sep; 69(3):499-509. PubMed ID: 26915300
[TBL] [Abstract][Full Text] [Related]
12. Assessment of BRAF
Pierry C; Caumont C; Blanchard E; Brochet C; Dournes G; Gros A; Bandres T; Verdon S; Marty M; Bégueret H; Merlio JP
Virchows Arch; 2018 Feb; 472(2):247-258. PubMed ID: 28711990
[TBL] [Abstract][Full Text] [Related]
13. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
[TBL] [Abstract][Full Text] [Related]
14. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
15. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and BRAF
Huo Z; Lu T; Liang Z; Ping F; Shen J; Lu J; Ma W; Zhao D; Zhong D
Diagn Pathol; 2016 Oct; 11(1):100. PubMed ID: 27760550
[TBL] [Abstract][Full Text] [Related]
18. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of
Liu X; Zhang Y; Zhou CX
Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
[TBL] [Abstract][Full Text] [Related]
20. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
